Febrile neutropenia risk assessment tool: Improving clinical outcomes for oncology patients

被引:6
作者
O'Brien, Catherine [1 ]
Dempsey, Orla [2 ]
Kennedy, M. John [1 ,3 ]
机构
[1] St James Hosp, HOPE Directorate, Haematol Oncol Dept, Dublin 8, Ireland
[2] Univ Dublin Trinity Coll, Sch Nursing & Midwifery, Ctr Practice & Healthcare Innovat, Dublin 2, Ireland
[3] Univ Dublin Trinity Coll, Acad Unit Clin & Mol Oncol, Dublin 2, Ireland
关键词
Febrile neutropenia; Risk assessment; Chemotherapy; Risk factors; G-CSF; COLONY-STIMULATING FACTORS; RELATIVE DOSE INTENSITY; BREAST-CANCER; PRACTICE GUIDELINE; 2010; UPDATE; FOLLOW-UP; CHEMOTHERAPY; PREDICTORS; LYMPHOMA; DELIVERY;
D O I
10.1016/j.ejon.2013.11.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To develop, implement and evaluate the effectiveness of a nurse-led risk assessment tool to reduce the incidence of febrile neutropenia (FN) and evaluate the nurse's role in FN risk assessment in a hospital-based oncology unit. Methods and sample: A FN risk assessment tool was developed, implemented and evaluated. A comparative prospective observational chart review was undertaken to evaluate the tool. Clinical data were collected from 459 patients' records from August 2008 through July 2009. Patients had no intervention during the first six months (n = 233). Patients in the following six months (n = 226) had the FN risk assessment completed and appropriate granulocyte-colony stimulating factor prescribed. A self-questionnaire was utilised to evaluate the nurses' role in FN risk assessment. Key results: The incidence of FN was reduced by 52% (p = 0.02). Hospital days, dose reductions and treatment delays were reduced. Nurses felt they were the most appropriate person to carry out the assessment. Conclusions: Through consistent risk assessment, nurses could determine which patients were at high risk of developing FN leading to significant reduction in life-threatening infections, hospitalisations, dose reductions and delays. Nurses can be confident and competent in decision-making to reduce life-threatening infections through the use of an FN risk assessment tool. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:167 / 174
页数:8
相关论文
共 44 条
  • [1] 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    Aapro, M. S.
    Bohlius, J.
    Cameron, D. A.
    Dal Lago, Lissandra
    Donnelly, J. Peter
    Kearney, N.
    Lyman, G. H.
    Pettengell, R.
    Tjan-Heijnen, V. C.
    Walewski, J.
    Weber, Damien C.
    Zielinski, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) : 8 - 32
  • [2] Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
    Aapro, Matti
    Crawford, Jeffrey
    Kamioner, Didier
    [J]. SUPPORTIVE CARE IN CANCER, 2010, 18 (05) : 529 - 541
  • [3] Al-Kali A., 2006, ONCOLOGY, V20, P1
  • [4] [Anonymous], 2006, COMMUNITY ONCOL
  • [5] Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients
    Bennett, Charles L.
    Calhoun, Elizabeth A.
    [J]. ONCOLOGIST, 2007, 12 (04) : 478 - 483
  • [6] 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
    Bonadonna, G
    Moliterni, A
    Zambetti, M
    Daidone, MG
    Pilotti, S
    Gianni, L
    Valagussa, P
    [J]. BRITISH MEDICAL JOURNAL, 2005, 330 (7485): : 217 - 220
  • [7] Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP
    Bosly, A.
    Bron, D.
    Van Hoof, A.
    De Bock, R.
    Berneman, Z.
    Ferrant, A.
    Kaufman, L.
    Dauwe, M.
    Verhoef, G.
    [J]. ANNALS OF HEMATOLOGY, 2008, 87 (04) : 277 - 283
  • [8] Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia
    Cappozzo, C
    [J]. ONCOLOGY NURSING FORUM, 2004, 31 (03) : 569 - 574
  • [9] Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
    Chan, Alexandre
    Chen, Christy
    Chiang, Joen
    Tan, Sze Huey
    Ng, Raymond
    [J]. SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1525 - 1532
  • [10] Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
    Chirivella, Isabel
    Bermejo, Begona
    Insa, Amelia
    Perez-Fidalgo, Alejandro
    Magro, Ana
    Rosello, Susana
    Garcia-Garre, Elisa
    Martin, Paloma
    Bosch, Ana
    Lluch, Ana
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 479 - 484